Practical DermatologyFDA Approves OTC Switch for Galderma’s Differin Epiduo Acne Gel

📋 Regulatory Action / Label Change

The FDA has switched adapalene/benzoyl peroxide gel (Differin Epiduo) from prescription to OTC status for patients 12 and older. The change expands adolescent access to a fixed-dose retinoid combination without a clinical visit or prescription.

Professional Impact

• Adolescent patients may initiate treatment independently before a clinical encounter, potentially presenting with an established regimen already in use
• OTC availability does not include prescribing guidance; counseling on irritation, sun sensitivity, and correct application remains a clinical responsibility
• The combination targets multiple acne pathways (comedonal, bacterial, inflammatory) — differentiate from single-agent OTC options when counseling patients and families
• Pediatricians and adolescent medicine providers should anticipate questions about product selection as it reaches major retail chains in summer 2026

Action Items

• Update patient and family counseling on the availability of this combination OTC option for adolescents 12+
• Review for drug interactions or contraindications before endorsing use in patients on concurrent topical or systemic acne therapy
• Clarify application instructions — once daily, with sunscreen; retinoid-class irritation is expected early in treatment
• Document OTC use in adolescent patients’ medication histories at well visits